# Resveratrol and Sirolimus in Lymphangioleiomyomatosis Trial

> **NCT03253913** · PHASE2 · COMPLETED · sponsor: **University of Cincinnati** · enrollment: 25 (actual)

## Conditions studied

- Lymphangioleiomyomatosis

## Interventions

- **DRUG:** Sirolimus
- **DRUG:** Resveratrol

## Key facts

- **NCT ID:** NCT03253913
- **Lead sponsor:** University of Cincinnati
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-31
- **Primary completion:** 2022-10-15
- **Final completion:** 2022-10-15
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2023-02-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03253913

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03253913, "Resveratrol and Sirolimus in Lymphangioleiomyomatosis Trial". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03253913. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*